Psychopharmacology

Here are highlights from this week in Psychiatric Times, including conference updates and trial news.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

Learn more about the findings from the first 3 EMERGENT trials, and their use in the 4th and 5th trials, presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

A new phase 2 trial reveals a novel antidepressant delivers rapid symptom relief for major depressive disorder, with patients experiencing significant improvement within just hours of their first dose.

Here are highlights from this week in Psychiatric Times, including trial updates and a new approach to treating a surprising condition.

Check out these updates on research including major depressive disorder (MDD).

What patients are at risk when taking SSRIs?

Here are highlights from this week in Psychiatric Times, including FDA news and a look back at Psychiatric Times through the years.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Here are highlights from this week in Psychiatric Times, including FDA approvals and conference coverage.

Here's how best to manage polypharmacy in patients with traumatic brain injury.

How often do you revisit a comprehensive medication reconciliation?

Facing limited resources, cultural barriers, and complex mental health cases, A newly qualified doctor’s year in rural South Africa offers a deep dive into psychiatry in underserved areas.

Check out the top 5 best practice recommendations for treating children and adolescents with psychotropic and combination therapies.

Here are highlights from this week in Psychiatric Times, including FDA approvals and trial updates.

What is the appropriate duration for antipsychotic use and how can you safely taper or discontinue them?

How can we optimize and expand our knowledge of neuroplasticity?

Learn more about Alto Neuroscience's ALTO-300, in ongoing phase 2b trials as an adjunct treatment for major depressive disorder.

With MM120 in phase 3 in the MindMed trial, what place do psychedelics hold in psychiatry?

An observational cohort study found patients at less risk of hospitalization for alcohol use disorder when also being treated with a GLP-1 agonist anti-diabetic/obesity agent.

In this CME article, learn more about recent developments with lithium as they relate to renal issues.

Data presented at ACNP meeting demonstrated safety, tolerability, and efficacy for SPN-820 for MDD.

A poster at the ACNP Annual Meeting utilized a novel risk-informed case-control design to improve biomarker differentiation for ADHD.